Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta

By Faraz Kermani / Email the Author / “The Pink Sheet” Jan. 9, 2012, Vol. 74, No. 2
Reimbursement / Word Count: 1217 / Article # 00120109022

Executive Summary

Decisions by Germany’s drug benefit assessor, IQWiG, to recommend novel prostate cancer treatment Zytiga and reject me-too diabetes treatment Trajenta may allay confusion over just how well the country’s new added value assessment process is working

Purchase this Article

$85.00 Buy Now

For $85.00, purchase this 1217-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to “The Pink Sheet” will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 9

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article